Clinical Trials Directory

Trials / Completed

CompletedNCT03882021

High-Density (HD) Wave Mapping in Subjects With Atrial Fibrillation as a Predictor of Recurrence After a Single Ablation Procedure Using a PVI-Only Strategy

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
300 (actual)
Sponsor
Abbott Medical Devices · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim is to use the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™ to characterize the atrial substrate and develop a model for predicting recurrence rates after a single procedure using a PVI only approach and a contact catheter.

Detailed description

This clinical investigation is intended to characterize the left atrial substrate using the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™ in an HD Wave configuration and correlate different factors with 12-month success after a single ablation procedure using a pulmonary vein isolation (PVI) approach without further substrate modification. This is a post-market, single-arm, multi-center, prospective interventional study of the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™. This study is aimed at determining correlations between pre-ablation mapping characteristics and outcomes after catheter ablation of atrial fibrillation. Approximately 300 subjects at up to 20 sites worldwide will be enrolled. Subjects will be followed until they complete their 12-month visit. Clinical Investigation visits will occur at Baseline (confirmation of eligibility), Index Procedure, 3 months, 6 months, and 12 months. Endpoints will be analyzed when all subjects have completed their 12-month follow up visits.

Conditions

Interventions

TypeNameDescription
PROCEDUREA specific electrophysiology mapping protocol is applicable with the GRID catheter.The procedure will be done according to a standard ablation approach. During the electrophysiology study, additional mapping data will be collected to support the study endpoints using the GRID catheter.

Timeline

Start date
2019-08-26
Primary completion
2021-11-30
Completion
2022-01-13
First posted
2019-03-20
Last updated
2024-09-19
Results posted
2024-09-19

Locations

15 sites across 9 countries: Austria, Czechia, France, Germany, Italy, Netherlands, Portugal, Spain, United Kingdom

Source: ClinicalTrials.gov record NCT03882021. Inclusion in this directory is not an endorsement.